Author

Amarnath Sugumaran

Observed names: AMARNATH SUGUMARAN, Sugumaran Amarnath

Observed institutions: Indian Institute of Technology Bombay, P. D. Hinduja Hospital and Medical Research Centre, Max Super Speciality Hospital, Rabindranath Tagore International Institute of Cardiac Sciences, Institute of Post Graduate Medical Education and Research, Sir Ganga Ram Hospital, Peerless Hospital & B.K.Roy Research Centre, Cipla (India), Sanofi (India), MGM New Bombay Hospital, AMRI Hospitals

ORCID: 0000-0001-9207-5605

Observed ORCID: 0000-0001-9207-5605

OpenAlex ID: A5066845026

Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines

2022 · Viswanathan Mohan, Banshi Saboo, et al. · Clinical Medicine Insights Endocrinology and Diabetes · 33

Mesenchymal stromal cell therapy (REGENACIP®), a promising treatment option in chronic limb threatening ischemia – a narrative review

2024 · Sanjay Desai, Digvijay Sharma, et al. · Stem Cell Research & Therapy · 13

PDF

Impact of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure: Targeting the Heart Failure Cascade

2023 · Uday Jadhav, Tiny Nair, et al. · Cureus · 8

PDF

The LongitudinAl Nationwide stuDy on Management And Real‐world outComes of diabetes in India over 3 years ( LANDMARC trial)

2023 · Ashok K. Das, Sanjay Kalra, et al. · Endocrinology Diabetes & Metabolism · 7

PDF

Loop Diuretics: An Overview of Its History and Evolution

2024 · Jyotirmoy Pal, Mangesh Tiwaskar, et al. · Journal of the Association of Physicians of India · 5

Effectiveness and Safety of the Telmisartan and Amlodipine Fixed-dose Combination in Managing Hypertension among Indian Patients (TACT India Study): Rationale and Study Design

2024 · Ashok Kumar Das, Mangesh Tiwaskar, et al. · Journal of the Association of Physicians of India · 4

Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice

2024 · Akshay Bafna, Ajit Mehta, et al. · Journal of Diabetology · 4

Mineralocorticoid Receptor Antagonists: The Pillar Drug in Heart Failure

2026 · Rishi Sethi, Rajat Jain, et al. · Journal of the Association of Physicians of India · 3

Inhaled Insulin Decoded: Dispelling Myths and Presenting Clinical Evidence

2025 · Jothydev Kesavadev, Hemant P Thacker, et al. · Cureus · 3

PDF

833-P: Efficacy and Safety of Prandial Technosphere Inhaled Insulin (Afrezza) Compared with Placebo in Adult Individuals with T2DM—Results from a Phase III Clinical Trial from India

2025 · KM PRASANNA KUMAR, MV RAMA MOHAN, et al. · Diabetes · 3

Rationale and Study Design of Real-World Effectiveness and Safety of Torsemide and Spironolactone Fixed Dose Combination in Indian Heart Failure Patients (RESTORE-HF Study): A Prospective, Longitudinal, Multicentre, Observational Study

2023 · C.K. Ponde, Devanu Gosh Roy, et al. · Indian Heart Journal · 3

The Potential Role of Torsemide in Optimizing Loop Diuretic Therapy for Heart Failure Patients

2023 · V. K Chopra, P. P Mohanan, et al. · Cureus · 3

PDF

Diabetes treatment with dapagliflozin and its combinations: Insights from clinical practice

2023 · Ajit Mehta, Akshay Bafna, et al. · Endocrine Abstracts · 3

The Pharmacological Properties and Safety Profile of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction

2026 · Dharmesh Solanki, Rajesh Badani, et al. · Journal of the Association of Physicians of India · 2

Future Directions and Innovations in Mineralocorticoid Receptor Antagonist Therapy

2026 · Shashank Joshi, Mangesh Tiwaskar, et al. · Journal of the Association of Physicians of India · 2

Current practice and perceptions on the use of mineralocorticoid receptor antagonists in the management of heart failure: A cross-sectional study among Indian physicians

2025 · Rajeev Garg, Subhash Sonawala, et al. · Heart India · 2

Fixed-dose Combination of Torsemide and Mineralocorticoid Receptor Antagonists

2024 · Sunip Banerjee, Girish B Navasundi, et al. · Journal of the Association of Physicians of India · 2

Torsemide as a Primary Choice in Edema Associated with Heart Failure

2024 · Janakiraman Ezhilan, Sunil Dighe, et al. · Journal of the Association of Physicians of India · 2

Two‐year trends from the LANDMARC study: A 3‐year, pan‐India, prospective, longitudinal study on the management and real‐world outcome in patients with type 2 diabetes mellitus

2023 · Ashok K. Das, Sanjay Kalra, et al. · Endocrinology Diabetes & Metabolism · 2

Evaluation of Effectiveness and Safety of Telmisartan and Amlodipine Fixed-Dose Combination in Indian Patients with Hypertension: TACT-India Study

2026 · Ashok Kumar Das, Mangesh Tiwaskar, et al. · Drugs - Real World Outcomes · 1

PDF

Mineralocorticoid Receptor Antagonists: An Overview of History and Evolution

2026 · BC Kalmath, Mangesh Tiwaskar, et al. · Journal of the Association of Physicians of India · 1

Current Practices and Perspectives of Clinicians on Glucose Monitoring in Indian Patients with Type 2 Diabetes Mellitus

2025 · Bharat Saboo, Pramila Kalra, et al. · International Journal of Diabetes and Technology · 1

Effectiveness and Safety of Vildagliptin Sustained Release in the Management of Type 2 Diabetes Mellitus: Real-World Evidence in Indian Patients [NOVELTY Study]

2025 · Rakesh Sahay, Anil Bhansali, et al. · Drugs - Real World Outcomes · 1

PDF

Torsemide in the Management of Essential Hypertension

2024 · Kuntal Bhattacharyya, Mangesh Tiwaskar, et al. · Journal of the Association of Physicians of India · 1

Postprandial Matters: Identifying Multifactorial Determinants and Rethinking Glucose Monitoring

2026 · Subhash K. Wangnoo, Ashok K. Das, et al. · Journal of Diabetology

Works count: 59

Citation count: 109

H-index: 5

I10-index: 2